<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20190411043240N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2019-05-23</date_registration>
      <primary_sponsor>The University of Kirsehir Ahi Evran</primary_sponsor>
      <public_title>Effect of  the Extracorporeal Shock Wave Therapy (ESWT) in Chronic Low Back Pain</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the Effect of Classical Physical Therapy Agents and Extracorporeal Shock Wave Therapy (ESWT) on Pain, Disability, Functional Status and Depression in Patients with Chronic Low Back Pain; Prospective randomized controlled trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-07-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>80</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/39510</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: simple, individual, sealed envelopes.</study_design>
      <phase>N/A</phase>
      <hc_freetext>chronic low back pain.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group:  extracorporeal shock wave therapy. The model name of the device is Modus ESWT. Device has CE ("Conformité Européene") mark. The global product (barcode) number is 8680050920224. The device is registered in Turkey Pharmaceuticals and Medical Devices National Data Bank (TİTUBB). Extracorporeal shock wave therapy (ESWT) is a noninvasive procedure using single-pulse acoustic waves produced outside the body and focused on a specific area in the body.Studies have shown that ESWT is an effective and long-term pain-reducing method for soft tissue diseases such as plantar fasciitis and achilles tendinopathy; ESWT is routinely applied in achilles tendinopathy and plantar fasciitis.Shock waves promote axonal regeneration of peripheral nerves by various molecular reactions.ESWT has been reported to induce analgesia by biochemical changes in the nerve fiber itself and to reduce inflammation of soft tissues.  It has also been shown that ESWT promotes revascularization, stimulates or re-activates the healing process of connective tissues, including tendons and bones, thereby alleviating pain and improving function.ESWT can be used to relieve pain as well as to improve muscle strength through proper motor stimulation by shock waves of muscles and tendons.ESWT device user's manual also includes low back pain in the ESWT indication list, but ESWT; There are few studies on the effects of low back pain on pain, disability and depression.ESWT will be applied in a total of 5 sessions 2-3 weeks after a minimum of 2 days. After the application of the joining gel, the shock wave probe will be placed perpendicular to the areas of the Quadratus Lumborum, Sacroiliac joint and the patient's pain, and the 20mm applicator will be applied at a pressure of 2.8 bar and at a frequency of 10 Hz with 2600 shots. Intervention 2: Intervention group: Classical Physical Therapy Agents.  Classic physical therapy agents TENS 20 minutes, Hot pack 20 min, ultrasound 5 min to be applied for 15 days.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Comparison of the Effect of Classical Physical Therapy Agents and Extracorporeal Shock Wave Therapy (ESWT) on Pain, Disability, Functional Status and Depression in Patients with Chronic Low Back Pain; Prospective randomized controlled trial

When:
When the study starts, study will become available and it will ends after 1 year after the end of study

To whom:
For medical doctors, physiotherapists

Conditions:
Data/documents could be used after taking permission

Where to obtain:
From researcher

How to obtain:
People which want to access data/document can write via e-mail.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mehmet Okcu</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Bağbaşı Mahallesi, Şht. Sahir Kurutluoğlu Cd. No: 100, 40100 Özbağ Belediyesi/Kırşehir Merkez/Kırşehir</address>
        <city>Kirsehir</city>
        <country1>Turkey</country1>
        <zip>40100</zip>
        <telephone>+90 386 441 02 44</telephone>
        <email>mehmet.okcu@ahievran.edu.tr</email>
        <affiliation>Ahi evran university</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mehmet Okcu</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Bağbaşı Mahallesi, Şht. Sahir Kurutluoğlu Cd. No: 100, 40100 Özbağ Belediyesi/Kırşehir Merkez/Kırşehir</address>
        <city>Kirsehir</city>
        <country1>Turkey</country1>
        <zip>40100</zip>
        <telephone>+90 386 441 02 44</telephone>
        <email>mehmet.okcu@ahievran.edu.tr</email>
        <affiliation>Ahi evran university</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Turkey</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Male and female patients with low back pain who have been diagnosed with chronic low back pain for at least 3 months between 18- 65 years old
Patients who are able to understand correctly the patient information form and cooperate
Patients consenting to participate in the study according to the informed consent form</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Operational history of lumbar spine region.
Vertebral compression fracture
Spinal tumors
Intervertebral disc infections
Inflammatory rheumatic disease
Pregnant patients
Heart disease
Structural abnormalities
Whether the patient is unwilling or unable to participate for any reason
Deciding whether the clinician does not benefit the patient</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M54.5</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Low back pain</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Devices</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group:  extracorporeal shock wave therapy. The model name of the device is Modus ESWT. Device has CE ("Conformité Européene") mark. The global product (barcode) number is 8680050920224. The device is registered in Turkey Pharmaceuticals and Medical Devices National Data Bank (TİTUBB). Extracorporeal shock wave therapy (ESWT) is a noninvasive procedure using single-pulse acoustic waves produced outside the body and focused on a specific area in the body.Studies have shown that ESWT is an effective and long-term pain-reducing method for soft tissue diseases such as plantar fasciitis and achilles tendinopathy; ESWT is routinely applied in achilles tendinopathy and plantar fasciitis.Shock waves promote axonal regeneration of peripheral nerves by various molecular reactions.ESWT has been reported to induce analgesia by biochemical changes in the nerve fiber itself and to reduce inflammation of soft tissues.  It has also been shown that ESWT promotes revascularization, stimulates or re-activates the healing process of connective tissues, including tendons and bones, thereby alleviating pain and improving function.ESWT can be used to relieve pain as well as to improve muscle strength through proper motor stimulation by shock waves of muscles and tendons.ESWT device user's manual also includes low back pain in the ESWT indication list, but ESWT; There are few studies on the effects of low back pain on pain, disability and depression.ESWT will be applied in a total of 5 sessions 2-3 weeks after a minimum of 2 days. After the application of the joining gel, the shock wave probe will be placed perpendicular to the areas of the Quadratus Lumborum, Sacroiliac joint and the patient's pain, and the 20mm applicator will be applied at a pressure of 2.8 bar and at a frequency of 10 Hz with 2600 shots.</i_keyword>
      <i_keyword>Intervention group: Classical Physical Therapy Agents.  Classic physical therapy agents TENS 20 minutes, Hot pack 20 min, ultrasound 5 min to be applied for 15 days.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The Beck Depression Scale will be  used to determine the levels of depression, and Oswestry, Health Assessment Questionnaire (Haq). Visual analogue scale (VAS) and Algometer will be used to question the pain status in individuals. Timepoint: before treatment, after treatment and at 3rd month. Method of measurement: The Beck Depression Scale will be  used to determine the levels of depression, and Oswestry, Health Assessment Questionnaire (Haq). Visual analogue scale (VAS) and Algometer will be used to question the pain status in individuals.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>The University of Kirsehir Ahi Evran</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2018-11-13</approval_date>
        <contact_name>Ethics committee of Kirsehir Ahi Evran University Faculty of Medicine</contact_name>
        <contact_address>Ahi Evran Üniversitesi Tıp Fakültesi Bağbaşı Yerleşkesi Merkez / Kirsehir/Turkey Kirsehir Kirsehir Turkey</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
